| Surgical and ablative therapies for the management of adrenal ‘oligometastases’–a systematic review A Gunjur, C Duong, D Ball, S Siva Cancer treatment reviews 40 (7), 838-846, 2014 | 89 | 2014 |
| Early post‐treatment pseudo‐progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis A Gunjur, E Lau, Y Taouk, G Ryan Journal of medical imaging and radiation oncology 55 (6), 603-610, 2011 | 53 | 2011 |
| Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature A Gunjur, O Klein, D Kee, J Cebon Journal for immunotherapy of cancer 7, 1-7, 2019 | 29 | 2019 |
| Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage A Balasubramanian, A Gunjur, A Weickhardt, N Papa, D Bolton, ... World Journal of Urology 40 (5), 1111-1124, 2022 | 20 | 2022 |
| The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post‐radiotherapy A Gunjur, M Bressel, G Ryan Journal of Medical Imaging and Radiation Oncology 56 (5), 567-573, 2012 | 17 | 2012 |
| Immune checkpoint inhibition with chemoradiotherapy in stage iii non–small-cell lung cancer: a systematic review and meta-analysis of safety results A Balasubramanian, J Onggo, A Gunjur, T John, S Parakh Clinical lung cancer 22 (2), 74-82, 2021 | 16 | 2021 |
| Cancer and the microbiome A Gunjur The Lancet Oncology 21 (7), 888, 2020 | 13 | 2020 |
| Nivolumab plus ipilimumab in advanced renal-cell carcinoma A Gunjur The Lancet Oncology 19 (5), e232, 2018 | 9 | 2018 |
| ‘Know thyself’–host factors influencing cancer response to immune checkpoint inhibitors A Gunjur, AJ Manrique‐Rincón, O Klein, A Behren, TD Lawley, SJ Welsh, ... The Journal of pathology 257 (4), 513-525, 2022 | 8 | 2022 |
| Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer–an Australian multi-centre observational study A Anton, S Wong, J Shapiro, A Weickhardt, A Azad, EM Kwan, L Spain, ... European Journal of Cancer 157, 485-492, 2021 | 8 | 2021 |
| Early in-patient palliative care consultation saves costs A Gunjur The Lancet Oncology 16 (7), e321, 2015 | 8 | 2015 |
| Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review A Gunjur, A Balasubramanian, U Hafeez, S Menon, L Cher, S Parakh, ... Journal of neuro-oncology 159 (3), 539-549, 2022 | 7 | 2022 |
| Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer A Anton, S Pillai, MC Semira, S Wong, J Shapiro, A Weickhardt, A Azad, ... BJUI compass 3 (3), 205-213, 2022 | 7 | 2022 |
| Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma A Balasubramanian, A Gunjur, HK Gan, Y Perchyonok, LM Cher Journal of Clinical Neuroscience 79, 269-271, 2020 | 7 | 2020 |
| Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma A Balasubramanian, A Gunjur, U Hafeez, S Menon, LM Cher, S Parakh, ... Neuro-oncology advances 3 (1), vdaa171, 2021 | 6 | 2021 |
| Talazoparib for BRCA-mutated advanced breast cancer A Gunjur The Lancet Oncology 19 (10), e511, 2018 | 6 | 2018 |
| Short vs long course adjuvant chemotherapy for colon cancer A Gunjur The Lancet Oncology 19 (5), e236, 2018 | 6 | 2018 |
| PTSD in parents after childhood cancer A Gunjur The Lancet Oncology 16 (7), e320, 2015 | 6 | 2015 |
| Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report A Gunjur, G Chong, A Lim, E Lau, P Mitchell, T John, S Arulananda Clinical lung cancer 21 (2), e57-e60, 2020 | 5 | 2020 |
| Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma H Gan, L Cher, PL Inglis, Z Lwin, E Lau, C Wichmann, U Ackermann, ... Journal of Nuclear Medicine 62 (supplement 1), 104-104, 2021 | 4 | 2021 |
